Ποια είναι η τιμή για Handa Pharmaceuticals, Inc. (6620)

Η τιμή για Handa Pharmaceuticals, Inc. (6620) είναι $2.95

Ποια είναι η κεφαλαιοποίηση αγοράς για Handa Pharmaceuticals, Inc. (6620)

Η κεφαλαιοποίηση αγοράς για Handa Pharmaceuticals, Inc. (6620) είναι $491.95M

Handa Pharmaceuticals, Inc. (6620) Τιμή και Κεφαλαιοποίηση Αγοράς

Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.

Η τιμή για 6620	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$31,609.31 $491.95M	NVDA	$5.264T	+1,069,904.30%
$28,230.97 $491.95M	AAPL	$4.701T	+955,544.35%
$25,083.78 $491.95M	GOOG	$4.177T	+849,009.13%
$22,923.34 $491.95M	MSFT	$3.817T	+775,876.11%
$17,212.24 $491.95M	AMZN	$2.866T	+582,550.04%

Η τιμή για 6620

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$31,609.31 $491.95M